



## Retrophin Receives Workplace Excellence Award

May 23, 2018

### **Peter Barron Stark Companies honors Retrophin for its continued commitment to workplace and cultural excellence**

SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been awarded the Peter Barron Stark Companies (PBS) [Award for Workplace Excellence](#), which recognizes top-tier organizations committed to a culture of workplace excellence based upon employee feedback from the PBS Employee Opinion Survey. Retrophin's survey results exceeded PBS' "Best of the Best Benchmark," which represents the top 25 percent of companies participating in the survey nationwide.

"We place the highest value on our team members' input and we are thankful for their continuous efforts to help make Retrophin an employer of choice," said Stephen Aselage, chief executive officer of Retrophin. "Engaged employees who are passionate about their work and dedicated to helping patients are vital to ultimately reaching our vision of being a leader within the rare disease community."

PBS collects survey data from more than 300 companies and 100,000 employee opinions nationwide on topics such as work environment, clarity of purpose and goals, communication, commitment to quality, motivation, training and compensation. Only five to eight companies receive the Award for Workplace Excellence each year. Winners are often companies that value employee engagement when recruiting and attracting high-quality employees who are interested in maintaining workplace excellence.

### **About Retrophin**

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Chenodal<sup>®</sup>, Cholbam<sup>®</sup> and Thiola<sup>®</sup>.

[Retrophin.com](http://Retrophin.com)

### **About Peter Barron Stark Companies**

For the past twenty-five years, clients have been partnering with Peter Barron Stark Companies to build organizational cultures where employees love to work and customers love to do business. To learn how Peter Barron Stark Companies helps transform organizations through customized services such as Employee Opinion Surveys, executive coaching, and leadership and employee training, visit [peterstark.com](http://peterstark.com).

Contact:

Chris Cline, CFA

Vice President, Investor Relations & Corporate Communications

760-260-8600

[IR@retrophin.com](mailto:IR@retrophin.com)

 [Primary Logo](#)

Source: Retrophin, Inc.